Lipocine SOARS on oral testosterone data despite FDA concerns
This article was originally published in Scrip
Executive Summary
Top-line results from the pivotal Phase III SOAR trial of Lipocine's oral testosterone product LPCN 1021 in hypogonadal men with low testosterone (Low T) show that it met its primary endpoint of getting serum hormone levels back to normal. Lipocine expects to file a new drug application (NDA) with the US FDA in the second half of 2015.
You may also be interested in...
AUA 2016: Studies Suggest Safety Ahead Of Lipocine's Oral Testosterone PDUFA
While Lipocine Inc. is at the nail-biting stage of development for its oral testosterone Tlando (LPCN 1021) – awaiting a US FDA approval decision – urologists continue to study testosterone therapy to determine whether treatment of hypogonadal men is safe with appropriate monitoring.
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.